Emcure Pharma Q2 FY25 Earnings Call Analysis

- Emcure expects overall revenue growth of 20%+ for FY25, with better momentum in H2 compared to H1. - Organic business growth is around 12%, supported by volume growth ahead of Indian pharmaceutical market (IPM) average. - Volume growth was about 3-4%, pricing up 2-3%, and new product introductions contributing 2-3%. - Domestic business aims to grow faster than industry high single-digit growth. - International business, especially emerging markets, expected to grow in low double digits organically. - European business is targeted to achieve double-digit growth from FY26 onward. - ARV (anti-retroviral) segment is expected to show strong recovery and growth visibility for FY25. - Field force expansion is targeted to support growth in tier 2 and tier 3 geographies for India business. - Acquisition-led growth will complement organic growth in the next 2-3 years. (Approx. 140 words)

- Emcure has operationalized four new plants recently, contributing to increased depreciation expenses, indicating recent capital investments in manufacturing capacity. - The company is focusing on building the Derma business through a new 100% owned subsidiary, Emcutix, which implies strategic investment in new therapeutic areas. - Expansion in salesforce with a vertical split to support strong brands and new product launches also suggests investment in commercial capabilities. - Emcure continues to look actively for acquisition opportunities domestically and internationally, which will involve strategic capital deployment. - No specific future capex amounts or timelines detailed, but focus on operating leverage and productivity improvements indicates ongoing and future investments aimed at margin enhancement. Overall, Emcure is investing strategically in capacity expansion, new therapy segments, and inorganic growth avenues without specifying exact capex plans.